EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bleeding complications in patients with out-of-hospital cardiac arrest treated with cangrelor and oral P2Y12 inhibitors

Georg Gelbenegger iD, Alexandra Julia Lipa, Anselm Jorda, Robert Zilberszac iD, Gottfried Heinz, Thomas Staudinger iD, Christian Zauner, Michael Holzer, Guy Friedrich iD, Fabian Plank, Irene M Lang iD, Bernd Jilma und 1 weitere

European Heart Journal: Acute Cardiovascular Care · 2025

DOI: 10.1093/ehjacc/zuaf082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Heart Journal: Acute Cardiovascular Care, 2025. Verfasst von Georg Gelbenegger und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Out-of-Hospital Cardiac Arrest, Purinergic P2Y Receptor Antagonists, Percutaneous Coronary Intervention, Adenosine Monophosphate. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Cangrelor is used to bridge the gap of insufficient platelet inhibition in patients with out-of-hospital cardiac arrest (OHCA) undergoing percutaneous coronary intervention (PCI). Methods and results In a retrospective chart review study, we investigated the incidence of bleeding and stent thrombosis in patients with OHCA undergoing PCI who received either cangrelor and transition to an oral P2Y12 inhibitor or an oral P2Y12 inhibitor alone. Subgroups consisted of patients treated with conventional cardiopulmonary resuscitation (CPR) and extracorporeal CPR. The primary endpoint was Bleeding Academic Research Consortium (BARC) 3–5 bleeding at 30 days. Between January 2016 and March 2025, 414 patients were included of which 267 received cangrelor and an oral P2Y12 inhibitor and 147 received an oral P2Y12 inhibitor alone. BARC 3–5 bleeding at 30 days occurred at a similar rate in the cangrelor group and the oral P2Y12 inhibitor group (18.4% vs. 19.0%, respectively; adjusted OR, 0.79; 95% CI, 0.45–1.39). BARC 3–5 bleeding at 6, 24 and 48 h was similar between the cangrelor group and the oral P2Y12 inhibitor group in patients treated with conventional and extracorporeal CPR. In patients treated with extracorporeal CPR, stent thrombosis occurred less frequently in the cangrelor group compared with the oral P2Y12 inhibitor group (2.1% vs. 4.5%, respectively; adjusted OR, 0.32, 95% CI, 0.03–3.14), but without reaching statistical significance.

Conclusion

In patients with OHCA undergoing PCI, BARC 3–5 bleeding occurred at a similar rate in patients receiving either cangrelor and transition to an oral P2Y12 inhibitor or an oral P2Y12 inhibitor alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Out-of-Hospital Cardiac ArrestPurinergic P2Y Receptor AntagonistsPercutaneous Coronary InterventionAdenosine MonophosphateHemorrhageHumansFemaleRetrospective StudiesMaleAgedMiddle AgedAdministration, OralIncidencePlatelet Aggregation InhibitorsCardiopulmonary ResuscitationFollow-Up Studies

Stichwörter der Autor:innen

ECPRExtracorporeal cardiopulmonary resuscitationP2Y12Percutaneous coronary interventionStent thrombosis

Substanzen

cangrelorPurinergic P2Y Receptor AntagonistsAdenosine MonophosphatePlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
  • Department of Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.
  • Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Department of Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
  • Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.
  • Department of Medicine III, Division of Cardiology, Medical University of Innsbruck, Innsbruck, Austria.

ORCID-Profile: Georg Gelbenegger, Robert Zilberszac, Thomas Staudinger, Guy Friedrich, Irene M Lang, Jolanta M Siller-Matula

Zitieren

APA

Gelbenegger, G., Lipa, A. J., Jorda, A., Zilberszac, R., Heinz, G., Staudinger, T., Zauner, C., Holzer, M., Friedrich, G., Plank, F., Lang, I. M., Jilma, B., & Siller-Matula, J. M. (2025). Bleeding complications in patients with out-of-hospital cardiac arrest treated with cangrelor and oral P2Y12 inhibitors. European Heart Journal: Acute Cardiovascular Care. https://doi.org/10.1093/ehjacc/zuaf082

Vancouver

Gelbenegger G, Lipa AJ, Jorda A, Zilberszac R, Heinz G, Staudinger T, et al. Bleeding complications in patients with out-of-hospital cardiac arrest treated with cangrelor and oral P2Y12 inhibitors. European Heart Journal: Acute Cardiovascular Care. 2025. doi:10.1093/ehjacc/zuaf082

BibTeX
@article{Gelbenegger2025,
  author = {Gelbenegger, Georg and Lipa, Alexandra Julia and Jorda, Anselm and Zilberszac, Robert and Heinz, Gottfried and Staudinger, Thomas and Zauner, Christian and Holzer, Michael and Friedrich, Guy and Plank, Fabian and Lang, Irene M and Jilma, Bernd and Siller-Matula, Jolanta M},
  title = {Bleeding complications in patients with out-of-hospital cardiac arrest treated with cangrelor and oral P2Y12 inhibitors},
  journal = {European Heart Journal: Acute Cardiovascular Care},
  year = {2025},
  doi = {10.1093/ehjacc/zuaf082}
}
Kostenlos starten →